ATE420666T1 - Radioaktiv markierte nanoteilchen - Google Patents

Radioaktiv markierte nanoteilchen

Info

Publication number
ATE420666T1
ATE420666T1 AT06764967T AT06764967T ATE420666T1 AT E420666 T1 ATE420666 T1 AT E420666T1 AT 06764967 T AT06764967 T AT 06764967T AT 06764967 T AT06764967 T AT 06764967T AT E420666 T1 ATE420666 T1 AT E420666T1
Authority
AT
Austria
Prior art keywords
radioactive labeled
labeled nanoparticles
nanoparticles
radiolabelled
radiolabelled nanoparticles
Prior art date
Application number
AT06764967T
Other languages
English (en)
Inventor
Paul Beer
Michael Lankshear
Hema Dattani
Alex Jackson
Michelle Avory
Original Assignee
Ge Healthcare Ltd
Univ Oxford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd, Univ Oxford filed Critical Ge Healthcare Ltd
Application granted granted Critical
Publication of ATE420666T1 publication Critical patent/ATE420666T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Glass Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT06764967T 2005-07-15 2006-07-14 Radioaktiv markierte nanoteilchen ATE420666T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0514513.1A GB0514513D0 (en) 2005-07-15 2005-07-15 Particulate agents

Publications (1)

Publication Number Publication Date
ATE420666T1 true ATE420666T1 (de) 2009-01-15

Family

ID=34897245

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06764967T ATE420666T1 (de) 2005-07-15 2006-07-14 Radioaktiv markierte nanoteilchen

Country Status (9)

Country Link
US (1) US20090110634A1 (de)
EP (1) EP1919517B1 (de)
JP (1) JP5037507B2 (de)
CN (1) CN101222943B (de)
AT (1) ATE420666T1 (de)
DE (1) DE602006004886D1 (de)
ES (1) ES2320805T3 (de)
GB (1) GB0514513D0 (de)
WO (1) WO2007010211A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101862463A (zh) * 2010-06-17 2010-10-20 复旦大学 一种18f标记纳米粒子的制备方法及其应用
US9011735B2 (en) 2010-12-30 2015-04-21 Ut-Battelle, Llc Volume-labeled nanoparticles and methods of preparation
KR101388238B1 (ko) 2013-04-17 2014-04-23 한국원자력연구원 테크네튬-99엠이 표지된 금 나노입자-금결합 펩타이드 복합체 제조 방법, 그 방법에 의해 제조된 복합체 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818199B1 (en) * 1994-07-29 2004-11-16 James F. Hainfeld Media and methods for enhanced medical imaging
DE19933346A1 (de) * 1999-07-16 2001-01-18 Aventis Res & Tech Gmbh & Co Stabile radioaktiv markierte Nanopartikel, Verfahren zur Herstellung und ihrer Verwendung
WO2001091808A2 (en) * 2000-06-01 2001-12-06 The Board Of Regents For Oklahoma State University Bioconjugates of nanoparticles as radiopharmaceuticals
AUPR113100A0 (en) * 2000-10-30 2000-11-23 Australian National University, The Radio-labelled ferrite particles and methods for the manufacture and use thereof
US20040146460A1 (en) * 2001-07-17 2004-07-29 Salafsky Joshua S Design of labels for detection with a surface-seletive nonlinear optical technique
US7695738B2 (en) * 2003-02-19 2010-04-13 Academia Sinica Carbohydrate encapsulated nanoparticles
US20070031327A1 (en) * 2003-06-03 2007-02-08 Luzzi David E Nanoradiopharmaceuticals and methods of use
EP2330208B1 (de) * 2004-05-24 2017-10-18 Midatech Ltd. Nanopartikel enthaltend RNA-Liganden

Also Published As

Publication number Publication date
DE602006004886D1 (de) 2009-03-05
EP1919517B1 (de) 2009-01-14
WO2007010211A1 (en) 2007-01-25
JP2009501332A (ja) 2009-01-15
EP1919517A1 (de) 2008-05-14
GB0514513D0 (en) 2005-08-24
CN101222943B (zh) 2013-04-10
US20090110634A1 (en) 2009-04-30
JP5037507B2 (ja) 2012-09-26
CN101222943A (zh) 2008-07-16
ES2320805T3 (es) 2009-05-28

Similar Documents

Publication Publication Date Title
IL181529A (en) A method for radiofluorination, a compound containing radioactive fluorine and its use in the preparation of a radioactive drug
FR18C1051I2 (fr) Anticorps obtenus par genie genetique diriges contre l'il-23p19
CY1110337T1 (el) Παρασκευη πρεγκαμπαλινης και σχετικων ενωσεων
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
CR20150102A (es) Anticuerpos que se unen a il-4 y/o il-13 (divisional 2)
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
WO2009129311A3 (en) Somatostatin receptor 2 antagonists
AR088405A2 (es) Proceso de sombreado y composicion de sombreado que comprende una ftalocianina
WO2015073746A3 (en) 18f labeling of proteins using sortases
MA32713B1 (fr) Anticorps anti-egfr/anti-igf-1r bispecifiques
RS53868B1 (en) ATP-BINDING CASSETTE TRANSPORT MODULATORS
BRPI0508628A (pt) conjugados de hidroxialquil amido e uma proteìna
BRPI0810332A2 (pt) "politioéter envolvido com amina/hidroxi"
BRPI0812777A2 (pt) Composição de um primeiro anticorpo monoclonal não-marcado que se liga a um antígeno de tumor e de um segundo anticorpo monoclonal que não sofre reação cruzada marcado com um marcador fluorescente nir
TW200738271A (en) Methods of making radiolabeled tracers and precursors thereof
WO2010000409A3 (en) Compounds and processes for production of radiopharmaceuticals
EA201301334A1 (ru) Меченные радиоактивными изотопами ингибиторы глутаминилциклазы
DE602006008639D1 (de) Automatisches radioaktives markierungsverafhren
DE602006000280D1 (de) Strahlenhärtbare Zusammensetzungen
SG131082A1 (en) Fabp4 as marker for a toxic effect
CY1113022T1 (el) Ακτινoφαρμακευτικες συνθεσεις οι οποιες περιεχουν πολυσακχαριτες εμβολιασμενους με πολυαμιδια
UY30596A1 (es) Marcacion con fluor radioactivo
ATE420666T1 (de) Radioaktiv markierte nanoteilchen
AR078716A1 (es) Anticuerpos antihepsina y metodos para su uso
ATE515558T1 (de) Schattierungszusammensetzung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties